2017
DOI: 10.1016/j.hlc.2016.11.008
|View full text |Cite
|
Sign up to set email alerts
|

Centhaquin Effects in a Swine Model of Ventricular Fibrillation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6

Relationship

3
3

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 24 publications
0
4
0
Order By: Relevance
“…Of note, new pharmacological agents have shown promising results and may allow the optimization of Pmsf, venous return, and tissue perfusion in hemorrhagic shock and cardiac arrest. Centhaquin, a novel agent under clinical development, was recently evaluated in a Phase II trial and proved highly effective in the resuscitation of hypovolemic shock by increasing MAP and decreasing the volume of administered fluids while maintaining tissue perfusion [32][33][34][35].…”
Section: Discussionmentioning
confidence: 99%
“…Of note, new pharmacological agents have shown promising results and may allow the optimization of Pmsf, venous return, and tissue perfusion in hemorrhagic shock and cardiac arrest. Centhaquin, a novel agent under clinical development, was recently evaluated in a Phase II trial and proved highly effective in the resuscitation of hypovolemic shock by increasing MAP and decreasing the volume of administered fluids while maintaining tissue perfusion [32][33][34][35].…”
Section: Discussionmentioning
confidence: 99%
“…All animals were examined by a veterinarian on the day of the experimentation and were found healthy. Animals were premedicated with intramuscular injections of 10 mg/kg ketamine hydrochloride (Imalgène, Merial Laboratorios SA, Lyon, France), 0.5 mg/kg midazolam (Dormicum, Roche, Athens, Greece), and 0.01 mg/kg atropine sulphate (Atropine sulphate, Demo, Athens, Greece), as previously described [ 15 ]. The animals were subsequently transported to the operation research facility and intravascular access through the auricular veins was obtained.…”
Section: Methodsmentioning
confidence: 99%
“…Electrical induction via two subcutaneous needles 50 ± 0 53.3 ± 6.0 46.9 ± 14.9 *One study was not included as it has 1,003 mA and 603 Hz which may be due to publication error [14] . Ten studies uses 9-V battery for electrical induction [15][16][17][18][19][20][21][22][23][24][25][26] . SD: standard deviation.…”
Section: Author Contributionsmentioning
confidence: 99%